Show simple item record

dc.contributor.authorDeveci, Aydin
dc.contributor.authorCoban, Ahmet Yilmaz
dc.date.accessioned2020-06-21T13:53:08Z
dc.date.available2020-06-21T13:53:08Z
dc.date.issued2014
dc.identifier.issn1478-7210
dc.identifier.issn1744-8336
dc.identifier.urihttps://doi.org/10.1586/14787210.2014.944505
dc.identifier.urihttps://hdl.handle.net/20.500.12712/14966
dc.descriptionWOS: 000355555500010en_US
dc.descriptionPubMed: 25088467en_US
dc.description.abstractLow virulent Citrobacter koseri can cause life threatening infections. Neonates and other immunocompromised patients are particularly susceptible to infection from C. koseri. Any infection due to C. koseri mandates antimicrobial therapy based on the sensitivity of the pathogen microorganism. Various types of antibiotics, including aminoglycosides carbapenems, cephalosporins, chloramphenicol and quinolones, are used for the treatment of C. koseri infections. The rational choice of antimicrobial therapy for Citrobacter infections is a challenge for clinicians because there is a sustained increase in antibacterial resistance. We reviewed antimicrobial agents used for C. koseri infections in this review.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.isversionof10.1586/14787210.2014.944505en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCitrobacter koserien_US
dc.subjectinfectionen_US
dc.subjectmanagementen_US
dc.subjecttreatmenten_US
dc.titleOptimum management of Citrobacter koseri infectionen_US
dc.typereviewen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume12en_US
dc.identifier.issue9en_US
dc.identifier.startpage1137en_US
dc.identifier.endpage1142en_US
dc.relation.journalExpert Review of Anti-Infective Therapyen_US
dc.relation.publicationcategoryDiğeren_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record